Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

(Reuters) – A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday, but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *